fda warning on semaglutide alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products Semaglutide FDA Approval vs Compounded

Semaglutide is a single-pathway GLP-1 receptor agonist, while tirzepatide is a dual GLP-1/GIP receptor agonist that activates two incretin receptors at once

The side effects at lower doses are minimal to nonexistent for most people

Kyle Gillett In this Huberman Lab Essentials episode, my guest is Kyle Gillett, MD, a dual board-certified physician in family medicine and obesity medicine, and an expert in hormone optimization

It is important to note that fatigue is specifically listed as a common adverse reaction in clinical trials for Wegovy (occurring in 5% of patients)

All of these factors can dynamically affect someone's metabolic complications," she says

Key wegovy side effects include: Gastrointestinal issues (nausea, vomiting, diarrhea, constipation) Headaches and dizziness Hypoglycemia (especially in patients with type 2 diabetes) Increased heart rate Pancreatitis Thyroid C-cell tumors (in animal studies) Its imperative for individuals to closely monitor their health and report any adverse reactions to their healthcare provider to manage and mitigate potential risks effectively